Pharmacodynamic interactions of quinolines with other antimalarial compounds in vitro
Author: Mariga, Shelton Tendai
Date: 2005-05-24
Location: Welander, Karolinska Universitetssjukhuset
Time: 13.30
Department: Institutionen för medicin / Department of Medicine
Abstract
Chemotherapy remains the most reliable means for the control of Plasmodium falciparum malaria. Unfortunately the parasite has been able to develop resistance to the majority of the antimalarials currently employed.
Success in the treatment of resistant infectious diseases such as leprosy, TB and HIV with combination therapy has generated wide interest in its application in malaria. Presently, WHO recommends the deployment of any novel antimalarial regimens for the treatment of P. falciparum only as drug combinations. Artemisinin (ART) combination therapy (ACT) represents the main combination option. Whilst, Quinoline antimalarials are the most important partners in this globally employed chemotherapy strategy.
The major objective of this work was to contribute, using the in vitro P.falciparum continuous culture model, the pharmacodynamic interactions between antimalarials as a tool for combination therapy strategies. Special emphasis was conferred on quinoline structures. These include amodiaquine (AQ), its active metabolite desethylamodiaquine (DAQ), quinine (QNN), lumefantrine (LUM), desbutyl-benflumetol (DBB) and pyroniridine (PYRON), with drugs of diverse structure ART, atovaquone (ATQ).
Drug susceptibility tests were performed for monocompounds along with drug combinations, according to chequerboard titration designs, of which the raw data obtained were calculated using two evaluation methods, O/E ratios (EC50, EC90, EC99) and isobolograms (sigmaFICs). AQ and DAQ showed high potency against P. falciparum, were superior to most recent antimalarials effective against chloroquine (CQ). Also confirmed was the high potency of DBB over LUM. DBB deserves further and more detailed preclinical/toxicological investigations.
AQ and DAQ were able to synergise with such compounds as, quinoline (QNN) and endoperoxide (ART) type of structures. AQ was also shown to synergise markedly with ATQ, a naphthoquinone ATQ. These results discern AQ and DAQ as flexaible partners in the context of combination therapy. In particular, their evident synergism with ART supports its present use in ACT strategies.
ART mainly synergised with the two Mannich base-containing quinolines herein tested, AQ and PYRON. Conversely, why ART does not synergise with CQ as much remains an open question, even though this observation could relate to the fact that CQ does not harbour a Mannich base in its structure.
AQ exhibited marked synergism with its active metabolite DAQ, even at trace concentrations. We further confirmed that this drug/metabolite phenomenon also occurs between quinoline methanols: LUM and its putative metabolite, DBB. This is the first time it has been shown that some antimalarials can significantly synergise with their own structurally similar active metabolites.
Success in the treatment of resistant infectious diseases such as leprosy, TB and HIV with combination therapy has generated wide interest in its application in malaria. Presently, WHO recommends the deployment of any novel antimalarial regimens for the treatment of P. falciparum only as drug combinations. Artemisinin (ART) combination therapy (ACT) represents the main combination option. Whilst, Quinoline antimalarials are the most important partners in this globally employed chemotherapy strategy.
The major objective of this work was to contribute, using the in vitro P.falciparum continuous culture model, the pharmacodynamic interactions between antimalarials as a tool for combination therapy strategies. Special emphasis was conferred on quinoline structures. These include amodiaquine (AQ), its active metabolite desethylamodiaquine (DAQ), quinine (QNN), lumefantrine (LUM), desbutyl-benflumetol (DBB) and pyroniridine (PYRON), with drugs of diverse structure ART, atovaquone (ATQ).
Drug susceptibility tests were performed for monocompounds along with drug combinations, according to chequerboard titration designs, of which the raw data obtained were calculated using two evaluation methods, O/E ratios (EC50, EC90, EC99) and isobolograms (sigmaFICs). AQ and DAQ showed high potency against P. falciparum, were superior to most recent antimalarials effective against chloroquine (CQ). Also confirmed was the high potency of DBB over LUM. DBB deserves further and more detailed preclinical/toxicological investigations.
AQ and DAQ were able to synergise with such compounds as, quinoline (QNN) and endoperoxide (ART) type of structures. AQ was also shown to synergise markedly with ATQ, a naphthoquinone ATQ. These results discern AQ and DAQ as flexaible partners in the context of combination therapy. In particular, their evident synergism with ART supports its present use in ACT strategies.
ART mainly synergised with the two Mannich base-containing quinolines herein tested, AQ and PYRON. Conversely, why ART does not synergise with CQ as much remains an open question, even though this observation could relate to the fact that CQ does not harbour a Mannich base in its structure.
AQ exhibited marked synergism with its active metabolite DAQ, even at trace concentrations. We further confirmed that this drug/metabolite phenomenon also occurs between quinoline methanols: LUM and its putative metabolite, DBB. This is the first time it has been shown that some antimalarials can significantly synergise with their own structurally similar active metabolites.
List of papers:
I. Gupta S, Thapar MM, Mariga ST, Wernsdorfer WH, Bjorkman A (2002). Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp Parasitol. 100(1): 28-35.
Pubmed
II. Mariga ST, Gil JP, Sisowath C, Wernsdorfer WH, Bjorkman A (2004). Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 48(11): 4089-96.
Pubmed
III. Mariga ST, Gil JP, Wernsdorfer WH, Bjorkman A (2005). Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro. Acta Trop. 93(3): 221-31.
Pubmed
IV. Mariga ST, Sisowath C, Zakeri S, Wernsdorfer WH, Bjorkman A, Gil JP (2005). Activity of desbutyl-benflumetol and lumefantrine and interaction of both in African, Asian and South American strains of Plasmodium falciparum strains in vitro. [Submitted]
I. Gupta S, Thapar MM, Mariga ST, Wernsdorfer WH, Bjorkman A (2002). Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp Parasitol. 100(1): 28-35.
Pubmed
II. Mariga ST, Gil JP, Sisowath C, Wernsdorfer WH, Bjorkman A (2004). Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 48(11): 4089-96.
Pubmed
III. Mariga ST, Gil JP, Wernsdorfer WH, Bjorkman A (2005). Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro. Acta Trop. 93(3): 221-31.
Pubmed
IV. Mariga ST, Sisowath C, Zakeri S, Wernsdorfer WH, Bjorkman A, Gil JP (2005). Activity of desbutyl-benflumetol and lumefantrine and interaction of both in African, Asian and South American strains of Plasmodium falciparum strains in vitro. [Submitted]
Issue date: 2005-05-03
Publication year: 2005
ISBN: 91-7140-279-9
Statistics
Total Visits
Views | |
---|---|
Pharmacodynamic ...(legacy) | 184 |
Pharmacodynamic ... | 105 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Pharmacodynamic ... | 2 | 0 | 0 | 1 | 1 | 5 | 0 |
Top country views
Views | |
---|---|
United States | 56 |
Germany | 40 |
China | 31 |
Sweden | 31 |
South Korea | 10 |
Denmark | 7 |
Ireland | 7 |
Russia | 7 |
Finland | 6 |
India | 5 |
Top cities views
Views | |
---|---|
Kiez | 15 |
Seoul | 9 |
Ashburn | 7 |
Dublin | 6 |
Tianjin | 6 |
Woodbridge | 5 |
Beijing | 4 |
Mountain View | 4 |
Stockholm | 4 |
Sunnyvale | 4 |